Chon Irina, Saito Reiko, Hibino Akinobu, Yagami Ren, Dapat Clyde, Odagiri Takashi, Kondo Hiroki, Sato Isamu, Kimura Shinji, Kawashima Takashi, Kodo Naoki, Masaki Hironori, Asoh Norichika, Tsuchihashi Yoshiko, Zaraket Hassan, Shobugawa Yugo
Division of International Health, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Department of Virology, Tohoku University Graduate School of Medicine.
Vaccine X. 2019 Jan 29;1:100011. doi: 10.1016/j.jvacx.2019.100011. eCollection 2019 Apr 11.
We estimated influenza vaccine effectiveness (VE) in 2015-2016 season against medically attended, laboratory-confirmed influenza, when quadrivalent inactivated vaccine (IIV4) was first introduced in Japan, using test-negative case-control design. Influenza A(H1N1)pdm09 cocirculated with B/Yamagata and B/Victoria during the study period in Japan.
We based our case definition on two laboratory tests, real-time reverse transcription polymerase chain reaction (RT PCR), and virus isolation and compared VEs based on these tests. In addition, VE was evaluated by rapid diagnostic test (RDT). Nasopharyngeal swabs were collected from outpatients who visited clinics with influenza-like illness (ILIs) in Hokkaido, Niigata, Gunma and Nagasaki prefectures.
Among 713 children and adults enrolled in this study, 578 were influenza positive by RT PCR including, 392 influenza A and 186 influenza B, while 135 were tested negative controls. The adjusted VE by RT PCR for all ages against any influenza was low protection of 36.0% (95% confidence interval [CI], 3.1% to 58.6%), for influenza A was 30.0% (95% CI: -10.0% to 55.5%), and influenza B was moderate 50.2% (95% CI: 13.3% to 71.4%). Adjusted VE for virus isolation for A(H1N1)pdm09 was 37.1% (95% CI: 1.7% to 59.7%), Yamagata lineage 51.3% (95% CI: 6.4% to 74.7%) and Victoria lineage 21.3% (95% CI: -50.0% to 58.9%). VE was highest and protective in 0-5 years old group against any influenza and influenza A and B/Yamagata, but the protective effect was not observed for other age groups and B/Victoria. RDT demonstrated concordant results with RT PCR and virus isolation. Sequencing of hemagglutinin gene showed that all A(H1N1)pdm09 belong to clade 6B including 31 strains (88.6%), which belong to clade 6B.1 possessing S162N mutations that may alter antigenicity and affect VE for A(H1N1)pdm09.
IIV4 influenza vaccine during 2015-2016 was effective against A(H1N1)pdm09 and the two lineages of type B. Younger children was more protected than older children and adults by vaccination.
我们采用检测阴性病例对照设计,对2015 - 2016年季节在日本首次引入四价灭活疫苗(IIV4)时,针对就医并经实验室确诊的流感的流感疫苗效力(VE)进行了评估。在日本的研究期间,甲型流感(H1N1)pdm09与乙型山形株和乙型维多利亚株共同流行。
我们的病例定义基于两项实验室检测,即实时逆转录聚合酶链反应(RT-PCR)和病毒分离,并比较了基于这些检测的疫苗效力。此外,通过快速诊断检测(RDT)评估疫苗效力。从北海道、新潟、群马和长崎县出现流感样疾病(ILI)并前往诊所就诊的门诊患者中采集鼻咽拭子。
在本研究纳入的713名儿童和成人中,578人经RT-PCR检测为流感阳性,其中392例为甲型流感,186例为乙型流感,而135人作为检测阴性对照。所有年龄组针对任何流感经RT-PCR调整后的疫苗效力为低保护水平的36.0%(95%置信区间[CI],3.1%至58.6%),针对甲型流感为30.0%(95% CI:-10.0%至55.5%),针对乙型流感为中等保护水平的50.2%(95% CI:13.3%至71.4%)。通过病毒分离对甲型(H1N1)pdm09调整后的疫苗效力为37.1%(95% CI:1.7%至59.7%),山形株系为51.3%(95% CI:6.4%至74.7%),维多利亚株系为21.3%(95% CI:-50.0%至58.9%)。在0至5岁年龄组中,针对任何流感以及甲型流感和乙型山形株,疫苗效力最高且具有保护作用,但在其他年龄组以及针对乙型维多利亚株未观察到保护作用。RDT与RT-PCR和病毒分离结果一致。血凝素基因测序表明,所有甲型(H1N1)pdm09均属于6B分支,包括31株(88.6%),属于具有可能改变抗原性并影响甲型(H1N1)pdm09疫苗效力的S162N突变体的6B.1分支。
2015 - 2016年期间的IIV4流感疫苗对甲型(H1N1)pdm09和两种乙型株系有效。通过接种疫苗,年幼儿童比年长儿童和成人受到的保护更多。